Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

M/s. Genix Pharma (Pvt) Ltd.

Private pharmaceutical manufacturer · Karachi · Pakistan

Pharmaceutical manufacturer founded in 2004 with a broad portfolio of prescription and OTC medicines and an export presence.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗ LinkedIn ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date4 Aug 2026Newest effective date among published current price records
Corporate profile evidence4 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
Genix Pharma (Private) Limited
Company type
Private pharmaceutical manufacturer
Address
44, 45-B, Korangi Creek Road, Karachi-75190, Pakistan · 75190
Phone
+92 21 111 10 10 11
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
88%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000351 Genix Pharma (Pvt) Ltd. · Sindh
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000351 298 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Contact Page Url source ↗ Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx299public portfolio records represented
REG230unique registrations represented
IDX20indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR284current validated price records
G97generic molecules in indexed catalogue
DF12dosage-form groups
TA14therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage95%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage98%
priced packs safely normalized per unit
Comparable-market coverage87%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixM/s. Genix Pharma (Pvt) Ltd.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/m-s-genix-pharma-pvt-ltdGenerated 23 Sep 2026Anti-infectives140 · 47%CNS & mental health43 · 14%Cardiovascular21 · 7%Gastrointestinal & hepatology19 · 6%Hematology & thrombosis15 · 5%Pain & musculoskeletal15 · 5%Endocrine & metabolic9 · 3%Other therapeutic areas35 · 12%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioM/s. Genix Pharma (Pvt) Ltd.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/m-s-genix-pharma-pvt-ltdGenerated 23 Sep 2026297presentationsTablet156 · 53%Injection56 · 19%Suspension23 · 8%Capsule22 · 7%Infusion16 · 5%Solution12 · 4%Other forms12 · 4%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionM/s. Genix Pharma (Pvt) Ltd.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/m-s-genix-pharma-pvt-ltdGenerated 23 Sep 2026258comparable productsBelow peer median47 · 18%Near peer median91 · 35%Above peer median120 · 47%Company median price position+4.8%Lowest-price equivalents32Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsM/s. Genix Pharma (Pvt) Ltd.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/m-s-genix-pharma-pvt-ltdGenerated 23 Sep 2026Neutro Pharma (Pvt.) Ltd.,50 shared52% overlapNabiqasim Industries (Pvt) Ltd.,49 shared51% overlapMacter International Limited46 shared47% overlapGenome Pharmaceuticals (Pvt.) Ltd.46 shared47% overlapGlobal Pharmaceuticals (Pvt.) Ltd.45 shared46% overlapPharmasol (Pvt) Ltd.44 shared45% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives140 products · 47%
CNS & mental health43 products · 14%
Cardiovascular21 products · 7%
Gastrointestinal & hepatology19 products · 6%
Hematology & thrombosis15 products · 5%
Pain & musculoskeletal15 products · 5%
Endocrine & metabolic9 products · 3%
Respiratory & allergy9 products · 3%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antivirals33 products · 11%
Antiepileptics24 products · 8%
Antimalarials20 products · 7%
Third-generation cephalosporins18 products · 6%
Fluoroquinolone antibacterials13 products · 4%
Macrolide antibacterials13 products · 4%
Antipsychotics12 products · 4%
Analgesics / NSAIDs11 products · 4%
Formulation footprint

Dosage forms

Tablet156 products
Injection56 products
Suspension23 products
Capsule22 products
Infusion16 products
Solution12 products
Drops4 products
Inhalation4 products
Cream1 products
Sachet1 products
Suppository1 products
Syrup1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 AclovirAciclovir 13presentations 200 mg, 200 mg/5 mL, 250 mg, 400 mg · Tablet, Syrup, Infusion #2 RecetamLevetiracetam 12presentations 100 mg/mL, 1000 mg, 250 mg, 500 mg · Solution, Tablet, Infusion #3 HadzoneCeftriaxone 11presentations 1 g, 2 g, 250 mg, 500 mg · Injection #4 ZyspanLinezolid 8presentations 100 mg/5 mL, 200 mg/100 mL, 400 mg, 400 mg/200 mL · Suspension, Solution, Tablet #5 EfecipCiprofloxacin 7presentations 125 mg/5 mL, 200 mg/100 mL, 250 mg, 250 mg/5 mL · Suspension, Infusion, Tablet #6 ExifinIbuprofen 7presentations 100 mg/5 mL, 200 mg/5 mL, 400 mg, 600 mg/100 mL · Suspension, Tablet, Infusion
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median4718% of comparable products
Near market median91within ±5% of median
Above market median12047% of comparable products
Lowest-price equivalents32ties included
Company median price position +4.8% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Vita-K 10 mg/mLPhytomenadione · Injection · 100's PKR 4.19/vial/unit-98.4% vs market median Amdivaz 250 mgMethyldopa · Tablet · 10X10's PKR 6.27/tablet-61.2% vs market median Monilstat 100,000 IU/mLNystatin · Oral drops · 30mL PKR 1.69/mL-43.4% vs market median Larith 500 mgClarithromycin · IV infusion · 1Vial PKR 170.61/vial/unit-41.2% vs market median Prozyl 500 mg/100 mLMetronidazole · IV infusion · 1Vial PKR 103.26/vial/unit-41.2% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 50shared generics Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 49shared generics Macter International Limited256 products · 93 generics 46shared generics Genome Pharmaceuticals (Pvt.) Ltd.181 products · 84 generics 46shared generics Global Pharmaceuticals (Pvt.) Ltd.224 products · 80 generics 45shared generics Pharmasol (Pvt) Ltd.257 products · 102 generics 44shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers228Distinct registrations among indexed, published, presentation-validated products only
Verified price observations297
Products with a verified price297
Products with multiple price observations0
Source records with multiple versions288
Latest portfolio source check22 Sep 2026
Latest effective price date4 Aug 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

230 unique registration(s) · 20 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Intelligence filter: Drug classAntimalarials Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Diphos Dihydroartemisinin + Piperaquine 40 mg + 320 mg Tablet 9's 061249 PKR 760.05 PKR 84.45/tablet Near median
Diphos Dihydroartemisinin + Piperaquine 40 mg + 320 mg Tablet 18's 061249 PKR 1,444.71 PKR 80.26/tablet 5% below median
Diphos Dihydroartemisinin + Piperaquine 40 mg + 320 mg Tablet 8's 061249 PKR 644.27 PKR 80.53/tablet Near median
Gen-Art Artemether 80 mg/mL Injection 6's x 1ml 073463 PKR 1,239.16 PKR 206.53/mL 11% above median
Gen-Art Artemether 80 mg/mL Injection 5's x 1ml 073463 PKR 991.34 PKR 198.27/mL 6% above median
Gen-Art Artemether 20 mg/mL Injection 6's x 1ml 073464 PKR 639.81 PKR 106.64/mL 15% above median
Gen-M Artemether + Lumefantrine 20 mg + 120 mg Tablet 4 x 6's 039028 PKR 941.74 PKR 39.24/tablet Near median
Gen-M Artemether + Lumefantrine 20 mg + 120 mg Tablet 16's 039028 PKR 660.88 PKR 41.31/tablet 5% above median
Gen-M Artemether + Lumefantrine 40 mg + 240 mg Tablet 8's 042423 PKR 563.04 PKR 70.38/tablet 10% above median
Gen-M Artemether + Lumefantrine 40 mg + 240 mg Tablet 12's 042423 PKR 801.90 PKR 66.83/tablet Near median
Gen-M Artesunate 60 mg Injection 1's 047630 PKR 239.36 PKR 239.36/vial/unit Near median
Gen-M Artemether + Lumefantrine 80 mg + 480 mg Tablet 6's 058397 PKR 679.74 PKR 113.29/tablet Near median
Gen-M Artemether + Lumefantrine 20 mg + 120 mg Tablet 16's 061403 PKR 638.28 PKR 39.89/tablet Near median
Gen-M Artemether + Lumefantrine 40 mg + 240 mg Tablet 12's 061616 PKR 844.56 PKR 70.38/tablet 10% above median
Gen-M Artesunate 30 mg Injection 1's 076072 PKR 153.56 PKR 153.56/vial/unit 5% above median
Gen-M Artesunate 120 mg Injection 1's 076073 PKR 411.96 PKR 411.96/vial/unit Near median
Gen-M Disp Artemether + Lumefantrine 20 mg + 120 mg Tablet 24's 061403 PKR 991.34 PKR 41.31/tablet 5% above median
Gen-M Disp Artemether + Lumefantrine 40 mg + 240 mg Tablet 8's 061616 PKR 543.81 PKR 67.98/tablet 6% above median
Q-Art Artesunate + Amodiaquine 50 mg + 135 mg Tablet 3's 061465 PKR 47.49 PKR 15.83/tablet 6% above median
Q-Art Artesunate + Amodiaquine 100 mg + 270 mg Tablet 6's 061466 PKR 161.10 PKR 26.85/tablet 101% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). M/s. Genix Pharma (Pvt) Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/m-s-genix-pharma-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.